Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

• Status: Completed
• Trial end date: 2010-06-16
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this randomized, two-arm parallel clinical study in 66 previously treated patients with severe or moderately severe hemophilia A is to compare the rate of bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose determined by the investigator) with that of alternate prophylaxis (20-80 IU/kg every 72 + 6 hours; actual dose determined by Baxter utilizing an algorithm and the patient's pharmacokinetic data). The rates of bleeding episodes for the on-demand regimen and the prophylaxis regimens will also be compared for the cross-over portion of the study. Enrolled patients will be treated originally on demand for a period of 6 months and then they will be randomized into one of the prophylaxis arms. Prophylactic treatment will last for a period of 12 months +/- 2 weeks.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Baxalta now part of Shire; Baxalta US Inc.
• Treatments: Factor VIII

Criteria

Inclusion Criteria:

• The subject has severe or moderately severe hemophilia A as defined by a baseline factor VIII level <= 2% of normal, as tested at screening

• The subject has a documented history of at least 150 exposure days to factor VIII concentrates (either plasma-derived or recombinant)

• The subject is within 7 to 65 years of age

• The subject has a Karnofsky performance score > (greater than) 60

• The subject is human immunodeficiency virus negative (HIV-) or is HIV+ with a CD4 count >= 400 cells/mm³ (CD4 count determined at screening, if necessary)

• The subject has been on a documented on-demand treatment regimen for at least 12 months immediately prior to enrollment

• The subject has a documented history (e.g. in medical charts or dispensing information, or signed investigator statement) of at least 8 joint hemorrhages in the 12 months immediately prior to enrollment

• The subject resides within the coverage area of the mobile compliance device; coverage area will be determined at screening

• The subject or the subject's legally authorized representative has provided written informed consent

Exclusion Criteria:

• The subject has a known hypersensitivity to factor VIII concentrates or mouse or hamster proteins

• The subject has a history of factor VIII inhibitors with a titer >= 0.6 BU (by Bethesda or Nijmegen assay) at any time prior to screening

• The subject has a detectable factor VIII inhibitor at screening, with a titer >= 0.4 BU (by Nijmegen Assay) in the central laboratory

• The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices.

• The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (e.g., qualitative platelet defect or von Willebrand's Disease)

• The subject has been treated during the last sixty (60) days prior to or is being treated at screening/enrollment with an immunomodulating drug.

• The subject has participated in another investigational study within thirty (30) days of enrollment

• The subject has previously participated in a clinical study with rAHF-PFM

• The subject's clinical condition may require a major surgery (defined as moderate to critical risk and perioperative blood loss ≥ 500 mL) during the period of the subject's participation in the study

• The subject is female of childbearing potential with a positive pregnancy test